(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 10 October 2002 (10.10.2002)

PCT

(10) International Publication Number WO 02/078568 A1

(51) International Patent Classification⁷: A61F 2/00

(21) International Application Number: PCT/GB02/01234

(22) International Filing Date: 2 April 2002 (02.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0108088.6 30 March 2001 (30.03.2001) GB

(71) Applicant (for all designated States except US): GYNE IDEAS LIMITED [GB/GB]; 1 Bell Leys, Wingrave, Buckinghamshire HP22 4QD (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BROWNING, James [GB/GB]; 12 Sherbrooke Gardens, Glasgow G41 4HU (GB).

(74) Agent: MURGITROYD & COMPANY; Scotland House, 165-169 Scotland Street, Glasgow G5 8PL (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

02/078568 A1

(54) Title: SURGICAL IMPLANT

(57) Abstract: A surgical implant suitable for treatment of hernias is provided. The implant comprises a mesh having a residual maximum mass density of 50g/m². The mesh comprises strands forming spaces and the strands comprise filaments forming pores. The spaces and pores are sized to minimise foreign body mass for implantation and to encourage integration of the implant. The mesh may be delivered using Dual Phase TechnologyTM for ease of handling, cutting and placement. The Dual Phase TechnologyTM may include encapsulation or coating with hydrogel.

1

1	"Surgical Implant"
2	
3	The present invention relates to the treatment of a
4	hernia such as a uterovaginal prolapse and, in
5	particular, to a surgical implant for use in such
6	treatment and to a related surgical procedure and
7	device.
. 8	
9	A hernia is basically a defect resulting in the
10	protrusion of part of an organ through the wall of a
11	bodily cavity within which it is normally contained.
12	For example, a fairly common and well known type of
L3	hernia is a defect in the lower abdominal wall
L4	resulting in a sac which may contain a portion of
15	the intestine protruding through the abdominal wall.
L6	This is referred to as an inguinal hernia.
L7	Similarly, a defect in the abdominal wall after
L8 .	surgery is referred to as an incisional hernia.
L9	Another type of hernia is a defect in the pelvic
20	floor or other supporting structures resulting in a
21	portion of the uterus, bladder, bowel or other
22	surrounding tissue protruding through, e.g., the

2

1 vaginal wall. This is usually referred to as 2 uterovaginal prolapse. 3 A common way of treating hernias is to repair the 4 defect by sutures, whether or not the hernial sac is 5 6 also sutured or repaired, in order that the 7 protruding organ is contained in its normal 8 position. As the defect generally comprises a 9 weakening and attenuation leading to parting of tissues in a fascial wall, it is usually necessary 10 11 to apply tension to the sutures in order to close 12 the parted tissues. Thus, the fascial wall is 13 generally pinched or tensioned around the area of 14 the defect in order to close the parted tissues. 15 This treatment is generally effective, but does have 16 some inherent problems. In particular, the pinching 17 18 or tensioning of tissue around the defect can lead 19 to discomfort and/or recurrence of the hernia. Additionally, in the case of uterovaginal prolapse, 20 21 such pinching or tensioning of the vaginal wall almost inevitably results in anatomical distortion 22 23 (such as narrowing of the vaginal cavity) with consequential pain and quality of life implications 24 for the patient and relatively high recurrence 25 26 and/or complication rates. 27 28 In order to address these problems, in the case of 29 inguinal hernia repair, it has been suggested to make use of a surgical implant to overlay or close 30 31 the weakened and parted tissues without the need to 32 pinch or tension the surrounding tissue of the

3

PCT/GB02/01234

1 fascia. Such surgical implants generally comprise 2 meshes and are now widely used in inguinal hernia repair. Meshes may be applied subcutaneously (i.e. 3 4 under the skin), internally or externally of the 5 abdominal wall and may be either absorbable or non-6 absorbable depending on the nature and severity of 7 the particular defect being treated. Meshes may be 8 applied in combination with sutures to hold the mesh 9 in place or, alternatively, with sutures that close 10 the parted tissues as in a "non-mesh" technique. Meshes are usually applied in open surgical 11 12 procedures, although they may sometimes be applied in laparoscopic surgical procedures. 13 14 15 A typical mesh for an inguinal hernia repair 16 . comprises woven or knitted polypropylene such as Marlex® or Prolene®. Such meshes have a number of 17 desirable properties that make them effective for 18 use in hernia repair. For example, they are made of 19 20 materials that are suitably inert so as to be less likely to cause adverse reactions when implanted in 21 the body. Furthermore, they are mechanically 22 23 strong, cheap, easily sterilisable and easy to work 24 with. 25 26 However, conventional meshes have a number of 27 inherent problems. For example, fistula or sinus 28 (i.e. abnormal passages between internal organs or between an internal organ and the body surface) can 29 develop as a result of a mesh being implanted and 30 left inside the body. More generally, the placement 31 of a foreign body subcutaneously can also lead to 32

4

inflammation or infection. Similarly, edge extrusion 1 2 (i.e. the erosion of body tissue around the edge of the mesh) can occur. Nevertheless, overall, the use 3 of meshes is generally considered to be beneficial 4 in the treatment of incisional and inquinal hernias. 5 6 7 It has also been suggested to use meshes in the treatment of uterovaginal prolapse. Meshes that 8 have been proposed for use in the repair of 9 uterovaginal prolapse are similar to those that are 10 used for the repair of inguinal hernia and such 11 However, there is concern that the above 12 mentioned problems with the use of meshes are 13 greater when a mesh is placed in the vaginal wall as 14 this tissue is generally thin only just below the 15 surface and therefore more prone to adverse 16 reactions. Furthermore, the placement of a foreign 17 body close to the rectum and urinary tract may 18 19 increase the risk of infection, inflammation, erosion, fistula or translocation. Thus, it is a 20 relatively widespread view that the use of meshes in 21 the treatment of vaginal prolapse is less desirable 22 than in the treatment of other hernias. 23 24 Nevertheless, as the use of meshes to treat 25 uterovaginal prolapse can avoid anatomical 26 distortion and the above mentioned problems related 27 to this, the Applicant considers there are 28 significant benefits in the use of meshes in the 29 30 treatment of uterovaginal prolapse should it be possible to mitigate the problems associated with 31 32 mesh treatment.

5

PCT/GB02/01234

The applicant has recognised that there are a number 1 2 of specific features of conventional meshes that exacerbate the problems of fistula, sinus, edge 3 extrusion, infection etc., particularly when these 4 meshes are implanted in the vaginal wall. 5 Applicant has therefore realised that it is possible 6 7 to provide a surgical implant that has the benefits 8 of mesh treatment, i.e. the avoidance of anatomical 9 distortion and its related problems, and also minimises the above mentioned problems. 10 11 One specific problem with conventional meshes that 12 the Applicant has recognised is that they have 13 jagged or rough edges. The rough edges arise as 14 15 conventional meshes are generally formed from sheets of multiple woven or intersecting fibres or strands. 16 When the meshes are cut to size in manufacture or 17 prior to fitting, the stray ends of the fibres or 18 strands are left extending from the edge of the 19 20 mesh, particularly where the edge is curved. In other words, the perimeter of the mesh comprises the 21 spaced ends of the fibres or strands and is not 22 smooth. It is thought that the jagged rough nature 23 24 of the edges of the implant increases the likelihood 25 of extrusion of the edge of the mesh in situ. 26 Conventional meshes are generally unnecessarily 27 28 strong and substantial for use in the vaginal wall and of significant mass. This results in an 29 30 unnecessary excess of foreign body material in the vaginal wall, increasing the risks associated with 31 32 the placement of foreign bodies inside the human

1 body, such as the risk of infection. Likewise, the

6

PCT/GB02/01234

- 2 bulk of such meshes can undesirably result in
- 3 discomfort for the patient as the mesh can often be
- 4 felt when in position. This is of particular
- 5 concern when a mesh is placed in sensitive vaginal
- 6 tissues or near to bowel or bladder.

7

WO 02/078568

- 8 A further disadvantage of the meshes presently used
- 9 to treat hernias relates to pore size. The pore
- size of meshes in use is unphysiological and does
- 11 not encourage acceptance of the implant in the body.

12

- 13 It is a aim of the present invention to overcome
- 14 problems associated with existing meshes used to
- 15 treat hernias.

16

- 17 According to the present invention there is provided
- 18 a surgical implant suitable for treatment of
- 19 hernias, the implant comprising a mesh having a
- 20 residual maximum mass density of 50g/m².

21

- 22 Preferably the maximum mass density is less than
- 23 30g/m². More preferably the maximum mass density is
- 1ess than $25g/m^2$.

25

- 26 By minimising mass density of a mesh for use in
- 27 treating hernias the advantages of using a mesh are
- 28 still apparant whereas the disadvantages are
- lessened in that jagged and rough edges are
- 30 minimised as is the risk of infection. The residual
- mass density is the mass density of the mesh after
- 32 implantation.

7

Preferably the surgical implant mesh comprises 1 2 strands and includes major spaces and pores. 3 4 The strands of the mesh may be formed by at least 5 two filaments, the major spaces formed between the 6 strands providing the surgical implant with the 7 necessary strength, the filaments arranged such that 8 pores are formed in the strands of the mesh. 9 10 Alternatively the strands may be formed by 11 monofilaments which form loops which give rise to the pores. 12. 13 Preferably strands are spaced by wider distance than 14 15 the fibres or filaments of conventional meshes used 16 in hernia repair. 17 18 Preferably the strands are spaced apart to form 19 major spaces of between 1 to 10 mm. 20 More preferably the strands are spaced apart to form 21 22 major spaces of between 2 to 8 mm. 23 24 The use of mesh having strands spaced between 1 to 25 10 mm apart has the advantage of reducing the 26 foreign body mass that is implanted in the human 27 body. Only sufficient tensile strength to securely 28 support the defect and tissue being repaired is 29 provided by the mesh. 30 31 It is desirable that the mesh of the present 32 invention has a mass of between one tenth (1/10th)

8

1 and one hundredth (1/100th) that of a conventional, 2 e.g. Prolene®, mesh of the same surface area. 3 mesh of the invention therefore avoids the unnecessary bulk of conventional meshes. 4 5 6 More specifically it is preferred that the mass density is less than 50g/m², more preferably less 7 than 30g/m and most preferably less than 20g/m². 8 9 It is also preferred that the strands of the mesh of 10 the present invention are narrower than those of 11 meshes of the prior art. 12 Preferably the strands have a diameter of less than 13 14 600um. 15 16 In one embodiment the strands are arranged to form a 17 diamond net mesh. 18 In an alternative embodiment the strands are 19 20 arranged to form a hexagonal net mesh. 21 22 The strands and filaments are preferably warp knit. 23 24 In an alternative embodiment the strands are 25 arranged to form a net mesh with suitable tensile 26 strength and elasticity. 27 28 Preferably the strands are arranged to form a net 29 mesh which has isotropic or near isotropic tensile 30 strength and elasticity. 31

. 9

1 Preferably the filaments have a diameter of between 2 0.02 to 0.15 mm. 3 4 More preferably the filament of the mesh is of a 5 diameter 0.08 to 0.1 mm. 6 7 This likewise has the advantage of reducing the 8 overall bulk of the implant, and hence the amount of 9 material retained in the human body. 10 Particular meshes which are embodiments of the 11 12 present invention include warp knit diamond or hexagon net diamond net meshes. Four particular 13 embodiments are set out below. 14 15 In two particular embodiments wherein the filaments 16 17 are formed from polypropylene having a diameter of 18 0.07 - 0.08mm wherein the strands are spaced to form 19 spaces of either 2mm or 5mm. 20 Alternatively, filaments are formed from polyester 21 22 having a diameter of 0.09mm wherein the strands are 23 spaced to form spaces of 5mm. 24 Alternatively, filaments are formed from polyester 25 having a diameter of 0.05 - 0.07mm wherein the 26 27 strands are spaced to form spaces of 2mm. 28 29 As the surgical implant is comprised of narrow 30 members arranged to be spaced by relatively wide 31 gaps, major spaces, tissue may be slow to grow into 32 the mesh. It is desirable for the mesh to have

10

means for promoting tissue ingrowth. More 1 specifically, it is desirable to provide pores in 2 the strands of the mesh to aid tissue ingrowth and 3 to which tissue may more easily adhere. 5 Preferably two filaments are interwoven/knitted to 6 produce strands of the mesh comprising pores. 7 8 9 Alternatively at least three filaments are interwoven/knitted to produce strands of the mesh 10 comprising pores. 11 12 For manufacturing reasons it is preferred that two 13 filaments are used to form the pores in the strands 14 15 of the mesh which aid tissue ingrowth, however if the one filament could be suitably knotted or 16 twisted to form pores of suitable dimensions it is 17 clear that this could be used to similar effect to 18 19 form the strands of the mesh. 20 Preferably the pores in the strands are of between 21 50 to 200µm in diameter. 22 23 More preferably the pores are of between 50 to 75µm 24 25 in diameter. 26 27 This is important in enabling efficient fibroblast throughgrowth and ordered collagen laydown in order 28 to provide optimal integration into the body. 29 is discussed in detail in copending Patent 30 Application No PCT/GB01/04554. 31

32

11

PCT/GB02/01234

1 Rings or loops of material comprising pores of between 50 to 200µm may be adhered to or formed on 2 3 the strands of the mesh to provide pores. 4 As mentioned above, reducing the mass of the mesh 5 6 has distinct advantages in relation to the 7 suitability of the mesh for implantation in the body, i.e. the reduction of foreign body mass and 8 9 improving the comfort of the patient. However, the handling characteristics of such a mesh, e.g. the 10 11 ease with which a surgeon can manipulate and place 12 the surgical implant in its desired location in the body, can be poor in some circumstances. More 13 specifically, a mesh having narrow members or 14 strands that are widely spaced will inevitably be 15 16 somewhat flimsy and lacking in rigidity compared to 17 conventional meshes. 18 Ideally the implant should be formed from materials 19 or uses technologies which provide the implant with 20 Dual Phase TechnologyTM, such that it has suitable 21 surgical handling characteristics and is also of 22 minimal mass and suited for implantation in the 23 body. The implant may be formed from a range of 24 materials to provide it with Dual Phase 25 $Technology^{TM}$. 26 The term Dual Phase Technology TM refers to a means 27 to provide temporary substance to the mesh. 28 29 Depending on the type of Dual Phase TechnologyTM employed the benefits imported, in addition to 30 allowing minimal residual mesh mass may include 31 assisting the mesh to be handled and cut, minimising 32

12 .

1 the effect of rough edges, assisting placing the 2 mesh in position and providing tackiness to assist in holding the mesh in position on implantation, 3 4 thus minimising or negating the need for any additional fixation by suturing or adhesion. 5 6 7 In a preferred embodiment of the invention having improved handling characteristics, the implant 8 9 therefore has an absorbable coating. 10 Preferably this coating encapsulates the mesh of the surgical implant. 11 12 Alternatively this coating is applied to at least 13 14 one face of the mesh. 15 The coating, covering or layer of absorbable 16 17 material stiffens and adds bulk to the mesh such 18 that it is easier to handle. 19 20 As the coating, covering or layer is absorbable, it 21 is absorbed by the body after implantation and does 22 not contribute to the foreign body mass retained in 23 the body. Thus, the advantages of a surgical 24 implant having minimal mass are retained. 25 26 Preferably the coating, covering a layer absorbs within 48 hours following implantation. 27 28 The coating, covering or layer may comprise any 29 30 suitable soluble and biocompatible material.

31

13

Suitable hydrogel materials can be obtained from 1 First Water in the UK. A typical hydrogel being 2 3 developed for use in this application is known as FIRST PHASETM or PHASE 1TM. 4 5 6 The absorbable material may be a soluble hydrogel 7 such as gelatin, 8 Alternatively the absorbable material is a starch or 9 10 cellulose based hydrogel. 11 12 In a further alternative the absorbable material is 13 an alginate. 14 In a further alternative the absorbable material may 15 16 contain hyaluronic acid. 17 18 The coating, covering or layer may have any 19 thickness or bulk that provides the surgical implant 20 with suitable handling characteristics. 21 Preferably, the coating is a sheet with a thickness 22 23 greater than that of the mesh. 24 Suitable handling characteristics may also be 25 26 provided to the mesh by a range of other methods. 27 The surgical implant may comprise a mesh and a backing strip the backing strip releasably 28 29 attachable to the mesh. 30 31 The backing strip may be formed from a range of 32 materials including plastics.

14

1	The surgical implant may be releasably attachable to
2	the backing strip by adhesive.
3	
4	The releasable attachment of a backing strip to the
5	mesh provides a more substantial and less flexible
6	surgical implant that is more easily handled by a
7	surgeon. Following suitable placement of the
8	surgical implant the backing strip can be removed
9	from the surgical implant, the surgical implant
10	being retained in the body and the backing material
11	being removed by the surgeon. The surgical implant
12	can therefore benefit from reduced mass while still
13	providing characteristics required for surgical
14	handling.
15	
16	In a further alternative the strands of the mesh of
17	the surgical implant are comprised of bicomponent
18	microfibres.
19	
20	Preferably the bicomponent microfibres comprise a
21	core material and surface material.
22	
23	The composite or biocomponent fibres preferably
24	comprise a nonabsorbable or long lasting absorbable
25	core and a shorter lasting absorbable surface
26	material.
27	
28	Whereas any licenced materials amy be used, suitable
29	materials presently available include polypropylene
30	for the core and polylactic acid or polyglycolic
31	acid for the surface materials.

15

Alternativley the bicomponent microfibres comprise 1 2 an material which is rapidly absorbed by the body and a material which is not absorbed for a suitable 3 longer period of time. 4 5 6 Preferably the surface material is capable of being 7 absorbed by the body in a period of less than 48 8 hours. 9 Preferably the core material is capable of remaining 10 in the body for a period of time sufficient to 11 12 enable tissue ingrowth. 13 The surface material of the bicomponent microfibres 14 15 or a portion of the composite polymers present during the insertion and placement of the surgical 16 17 implant provides the surgical implant with characteristics required for surgical handling. 18 19 Following a period of insertion in the body, the 20 21 surface material of the bicomponent microfibre is 22 absorbed by the body leaving behind the reduced foreign mass of the core material of the strands of 23 24 the mesh. 25 It is preferred that the surface material of the 26 27 bicomponent microfibre is absorbed by the body within a number of hours such that only a core 28 portion is left in the body for an extended length 29 30 of time. Typically materials presently available which could be used to form the microfibres are 31 32 absorbed by the body over a period of days or weeks.

16

The filaments of the mesh comprise a plastics or 1 2 synthetic material. 3 Preferably the filaments of the mesh comprise of 4 5 polypropylene or polyester. 6 Alternatively the filaments of the mesh comprise an 7 8 absorbable material. 9 10 It can be appreciated that filaments which comprise 11 in part of absorbable material would allow better surgical handling, but would enable the implant to 12 13 also have minimal mass following implantation in the 14 body. 15 Preferably the surgical implant comprises material 16 17 that has memory. 18 Preferably the surgical implant has memory which 19 urges the surgical implant to adopts a flat 20 21 conformation. 22 Preferably the implant has a generally curved 23 24 perimeter, i.e. to have few or no corners or apexes, 25 as sharp corners increase the likelihood of edge erosion and infection. The specific shape will, 26 27 however, vary according to the use to which the 28 implant is to be put. 29 Due to the variety of sizes of such defects, and of 30 the various fascia that may need repair by the 31 32 implant, the implant may have any suitable size,

17

Preferably the surgical implant is of width between 1 1 cm to 10 cm and of length between 1 cm to 10 cm. 2 3 4 It may be desirable to provide a variety of implants having different sizes in order that a surgeon can 5 б select an implant of suitable size to treat a 7 particular patient. This allows implants to be completely formed before delivery, ensuring, for 8 example, that the smooth edge is properly formed 9 under the control of the manufacturer. The surgeon 10 would have a variety of differently sized (and/or 11 shaped) implants to hand and select the appropriate 12 implant to use after assessment of the patient. 13 14 Typically an anterior uterovaginal prolapse is 15 ellipse shaped or a truncated ellipse whereas a 16 17 posterior prolapse is circular or ovoid in shape. 18 19 Accordingly the implant shape may be any one of 20 elliptical or tuncated ellipse, round, circular, 21 oval, ovoid or some similar shape to be used 22 depending on the hernia or polapse to be treated. 23 24 Different shapes are suitable for repairing different defects in fascial tissue and thus by 25 providing a surgical implant which can be cut to a 26 range of shapes a wide range of defects in fascial 27 tissue can be treated. 28 29 30 Preferably the mesh can be cut to any desired size. The cutting may be carried out by a surgeon or nurse 31 under sterile conditions such that the surgeon need 32

18

not have many differently sized implants to hand, 1 2 but can simply cut a mesh to the desired size of the implant after assessment of the patient. 3 In other words, the implant may be supplied in a large size 4 and be capable of being cut to a smaller size, as 5 desired. 6 7 8 In this regard, whilst the surgical implant of the 9 invention is particularly useful for the repair of uterovaginal prolapse, it may be used in a variety 10 of surgical procedures including the repair of 11 12 hernias. 13 Preferably the surgical implant is suitable for use 14 15 in the treatment of hernias including incisional and inguinal hernias and/or for the treatment of 16 17 uterovaginal prolapse. 18 More broadly, the Applicant has therefore recognised 19 20 that the implant can have any shape that conforms with an anatomical surface of the human or animal 21 body that may be subject to a defect to be repaired 22 23 by the implant. 24 As discussed a disadvantage of the meshes used in 25 26 hernia repair is that they have jagged or rough edges. Due to the wide spacing between strands of 27 28 the mesh described above and the small diameter of the filaments, the edge problems are mitigated to an 29 30 extent by the present invention. 31

19

1	To further reduce edge problems it would be
2	preferable if a mesh had a circumferential member
3	which extends, in use, along at least part of the
4	perimeter of the implant to provide a substantially
5	smooth edge.
6	
7	In other words, the mesh has at least one
8	circumferential member (i.e. fibre, strand or such
9	like) that extends around at least part of its
10	circumference.
11	
12	Preferably at least part of the perimeter of the
13	implant is defined by the circumferential member,
14	
15	Alternatively at least part of the perimeter of the
16	implant is defined by more than one circumferential
17	member, at the edge of the mesh.
18	
19	The edge of the mesh, and hence the perimeter of the
20	implant, can therefore be generally smooth and this
21	has significant advantages over conventional
22	
4 4	surgical meshes. Specifically, the Applicant has
23	surgical meshes. Specifically, the Applicant has recognised that an implant having a smooth edge is
•	
23	recognised that an implant having a smooth edge is
23 24 25	recognised that an implant having a smooth edge is
23 24 25	recognised that an implant having a smooth edge is less likely to cause edge extrusion or erosion.
23 24 25 26	recognised that an implant having a smooth edge is less likely to cause edge extrusion or erosion. Any amount of the perimeter of the implant may be
23 24 25 26 27	recognised that an implant having a smooth edge is less likely to cause edge extrusion or erosion. Any amount of the perimeter of the implant may be
23 24 25 26 27 28	recognised that an implant having a smooth edge is less likely to cause edge extrusion or erosion. Any amount of the perimeter of the implant may be defined by the circumferential member(s).
23 24 25 26 27 28 29	recognised that an implant having a smooth edge is less likely to cause edge extrusion or erosion. Any amount of the perimeter of the implant may be defined by the circumferential member(s). However, in order to maximise the benefits of the

20

More preferably at least 80% of the perimeter of the 1 2 implant is defined by the circumferential member(s). 3 4 Most preferably 100% of the perimeter of the implant 5 . is defined by the circumferential member(s). 6 The majority or the whole of the perimeter of the 7 mesh being smooth minimises the risk of a rough edge 8 causing edge erosion or infection. 9 10 11 The circumferential member(s) may be arranged in one 12 of a variety of ways to provide the smooth edge or 13 perimeter. 14 Preferably the circumferential members are arranged 15 16 such that they each follow the edge of a desired shape of the surgical implant, the perimeter of the 17 implant formed from as few members as possible. 18 19 20 This simplifies the construction of the mesh, which is desirable not only for manufacture, but also 21 22 because simpler structures are less likely to have defects which might be problematic after 23 24 implantation. 25 26 Preferably the perimeter of the mesh is defined, in 27 use, by one circumferential member. 28 Preferably the mesh has a plurality of 29 circumferential members arranged at different radial 30 locations. 31 32

21

1 In order to provide an implant of given dimensions, 2 the periphery of the mesh outward of the desired circumferential member is cut away such that one or 3 more selected circumferential members form the 4 5 perimeter of the implant as desired. 6 7 More preferably, the circumferential members are 8 arranged concentrically. 9 10 A concentric arrangement of a plurailty of circumferential members conveniently allows 11 12 maintenance of the shape of the implant for different sizes of implant and provides the mesh 13 14 with an even structure. 15 The remainder of the structure of the mesh may take 16 17 a variety of forms. 18 19 The circumferential members can be arranged to join with one another in order to form an integral mesh. 20 21 22 Alternatively the mesh may additionally comprise 23 transverse members which extend across the 24 circumferential members joining the circumferential 25 members. 26 27 The transverse members may extend radially from a 28 central point to the perimeter of the implant. 29 30 Alternatively, the transverse members may extend 31 toward the perimeter of the implant. 32

22

2 provide substantially even structural strength and

Preferably the transverse members are arranged to

PCT/GB02/01234

3 rigidity to the implant.

4

1

WO 02/078568

5 It may be desirable to secure the mesh in place once

6 it has been suitably located in the patient.

7

8 Preferably the mesh can be sutured to strong lateral

9 tissue.

10

11 Alternatively, the mesh may be glued in place using

12 a biocompatible glue.

13

14 This is advantageous, as it is fairly quick to apply

15 glue to the area around the surgical implant.

16

17 Preferably the mesh comprises at least one capsule

18 containing biocompatible glue for securing the

19 implant in place.

20

21 Preferably 4 capsules containing glue are provided

around the perimeter of the surgical implant.

23

24 Preferably the capsules comprise hollow thin walled

25 spheres of around 3 to 5 mm diameter including

26 gelatin.

27

28 Preferably the glue is a cyanoacrylate glue.

29

30 Conventionally, open procedures have been preferred

31 for the treatment of hernias with meshes, as

32 relatively broad access is required to the site of

23

1	the defect to suitably implant and secure a mesh by
2	sutures or such like.
3	
4	However, it is desirable to treat hernias, as when
5	carrying out any surgery, with as little trauma to
6	the patient as possible. Thus, the use of minimally
7	invasive techniques has been suggested for the
8	treatment of hernias. However, such surgical
9	techniques have not been considered to be useful in
10	the treatment of uterovaginal prolapse with a mesh,
11	as it has not been considered practical to position
12	a mesh subcutaneously in the vaginal wall due to the
13	difficulty in gaining direct access to this area.
14	
15	According to another aspect of the present
16	invention, there is provided a minimally invasive
17	method of treating uterovaginal prolapse, the method
18	comprising the steps;
19	
20	making an incision in the vaginal wall close to
21	the opening of the vaginal cavity and,
22	
23	making a subcutaneous cut, through the
24	incision, over and surrounding the area of the
25	prolapse, which cut is substantially parallel
26	to the vaginal wall; and
27	
28	inserting a mesh according to the present
29	invention, through the incision, into the space
30	defined by the cut.
31	

24

PCT/GB02/01234

Thus, a mesh or the surgical implant such as that 1 2 according to the invention can be inserted through a small incision (e.g. around 1cm to 2 cm in length) 3 at or in the region of the periphery or opening of 4 the vaginal cavity. An incision in this position is 5 6 easier for a surgeon to access than an incision 7 deeper in the vaginal cavity, yet the Applicant has 8 realised that it is also convenient to treat vaginal 9 prolapse by implanting a mesh in a surgical procedure carried out entirely through such an 10 11 incision. 12 Preferably, the incision is at the anterior or 13 14 posterior extremity of the prolapse sac of the 15 vaginal cavity. 16 This is desirable as prolapse most often occurs in 17 the anterior or posterior vaginal wall, so 18 positioning the incision in such a location allows 19 20 the most convenient access to these parts of the 21 vaginal wall. 22 23 The provision of suitable handling characteristics 24 for the mesh is particularly advantageous when the 25 mesh is intended to be used in a conventional open 26 surgical procedure, as the surgeon needs to handle the implant directly in order to place it in its 27 28 desired location. 29 However, the suitable placement particularly in the 30 31 treatment of uterovaginal prolapse, by minimally invasive techniques require the mesh to be as 32

25

PCT/GB02/01234

1 flexible as possible and therefore to have no 2 absorbable coating or encasement. 3 A flexible, less bulky mesh may be more easily 4 5 handled by tools that may be used to carry out the б procedure. 7 Tools that may be used to carry out this procedure 8 have a number of specific needs that need to be met 9 10 that are not presently met by conventional minimally 11 invasive surgical tools. 12 13 These specific needs can best be understood by 14 considering the steps of the surgical procedure of 15 the invention in turn. 16 17 The incision is made in the vaginal wall at the 18 opening of the vaginal cavity. This can be carried 19 out using a conventional implement such as a 20 scalpel. It is preferable that the incision is as 21 small as possible as this reduces trauma to the 22 patient. 23 A cut is then made in the vaginal wall over the 24 defect causing the prolapse or hernia. For example, 25 scissors or another specialised cutting tool can be 26 inserted through the incision and manipulated to 27 28 provide a cut over the defect. The cut is below the 29 surface of the skin and may provide a space between 30 an upper (or outer) layer and a lower (or inner) layer of the vaginal wall, or between the skin and 31

26

1 the vaginal wall, in the region of the defect, into which cavity the mesh can be inserted. 2 3 Next, the mesh is placed in the space defined by the 4 It is preferred that the mesh of the invention ·5 is supplied rolled up in order that it can be 6 7 inserted through a small incision and unfurled in situ, i.e. in its intended position. Thus, it may 8 9 be possible for the surgeon to insert the mesh through the incision by hand. However, this is 10 likely to result in the incision needing to be large 11 enough for the surgeon to insert a finger to 12 manipulate the mesh in the space. This may cause 13 14 unnecessary trauma to the patient and can be 15 difficult for a surgeon to carry out. 16 According to another aspect of the present 17 invention, there is provided a surgical tool for 18 delivering a mesh subcutaneously through an 19 incision, the tool being adapted to radially confine 20 the mesh during delivery and being operable to 21 22 release the mesh in its intended position. 23 24 Such a tool for placement of a mesh or the surgical 25 implant of the present invention can insert and position the mesh or surgical implant in a 26 convenient and controlled manner through a small 27 incision. Furthermore, the incision through which 28 29 the mesh is inserted need only be as large as the diameter of the tool, or the tool when carrying the 30 mesh, which can be significantly smaller than where 31

27

PCT/GB02/01234

a surgeon's finger must be able to fit through the 1 2 incision. 3 Preferably the tool comprises a housing and 4 unfurling means the housing and unfurling means 5 insertable through an incision in the patient, the 6 7 housing and unfurling means adapted to accommodate a 8 rolled up mesh and separable to release the mesh the 9 unfurling means capable of unfurling the rolled up mesh without any significant movement around the 10 11 area of the incision 12 13 Preferably, the tool comprises two or more parts, the parts movable such that in a first position they 14 house the mesh or surgical implant and, in a second 15 position the mesh or surgical implant is released. 16 More preferably the tool comprises two semi-circular 17 channels, an inner channel having an external 18 diameter suitable for fitting inside an outer 19 20 channel. 21 . 22 The channels may be rotatable about a common axis such that in a first position the open faces of the 23 24 channels face one another to form a closed housing 25 and in a second position the inner channel sits inside the other channel to release the mesh. 26 27 Alternative the tool comprises a shaft and 28 releasable securing means, the shaft adapted such 29 that the mesh can be rolled around the shaft and 30 releasable securing means to secure the rolled mesh 31 32 in place.

28

1 In use, the tool is inserted through the incision

2 with the mesh rolled around the outside of the

3 shaft. Once the tool has been inserted, the mesh is

PCT/GB02/01234

4 released by turning the shaft to unroll the mesh at

5 the same time as moving the shaft across the space

6 in which the mesh is being placed.

7

WO 02/078568

8 A needle may be used to secure the free, outer end

9 of the mesh whilst it is unfurled. The needle may

10 be inserted through the vaginal wall to pin the mesh

in place. Similarly, where the mesh is released

12 from within a housing, needles may be used to ease

13 the mesh out of the open housing.

14

15 In an alternate embodiment, the tool comprises two

or more arms, each of which is releasably attached

17 at one end to an edge of the surgical implant. The

arms may be movable from a first position in which

19 they radially confine the mesh to a second position

20 to unfurl the mesh in its intended position.

21

22 In one example, the arms are pivotally

interconnected such that they can be manipulated to

24 move the ends of the arms from the first position to

25 the second position.

26

27 In another example the arms may be arranged to

28 extend radially outward from a housing to move from

29 the first position to the second position. The

30 extendable arms may comprise wires arranged to be

31 extendable and retractable from and into the housing

32 by operation at an end of the housing.

29

1	In another example, the arms may be resilient or
2	sprung elements that can be released from the first
3	position and move into the second position to which
4	they are biased, i.e. to unfurl the mesh.
5	•
6	As can be appreciated, all of the above embodiments
7	of the tool are able to unfurl the mesh without any
8	significant movement around area of the incision.
9	For example, the pivot can be arranged to coincide
10	with the incision, the tool rolled around an arc
11	centred at the incision or the arms operated or
12	housing opened forward of the incision. Thus, the
13	incision can be small as no lateral movement is
14	required at the area of the incision.
15	
16	Embodiments of the present invention will now be
17	described, by way of example only, with reference t
18	the accompanying drawings, in which:
19	
20	Figure 1 is an illustration of a hernia;
21	
22	Figure 2 is an illustration of the hernia of
23	figure 1 when intra-abdominal pressure is
24	raised;
25	
26	Figure 3 is an illustration of the hernia of
27	figure 1 after repair in accordance with the
28	prior art;
29	
30	Figure 4 is an illustration of the hernia of
31	figure 1 after an alternate repair in
32	accordance with the prior art;

30

1	
2	Figure 5 is a schematic illustration of the
3	female human vaginal area;
4	
5	Figure 6 is a cross-sectional view of the
6	female human vaginal area along the line A-A of
7	Figure 5;
8	
9	Figures 7a and 7b illustrate surgical implants
10	according to the invention having a first
11 ,	shape;
12	
13	Figures 8a, 8b, 8c and 8d illustrate surgical
14	implants according to the invention having a
15	second shape;
16	
17	Figures 9a, 9b 9c and 9d illustrate surgical
18	implants according to the invention having a
19	third shape;
20	
21	Figure 10 illustrates a first surgical tool
22	according to the invention in cross-section;
23	
24	Figure 11 illustrates a second surgical tool
25	according to the invention;
26	
27	Figure 12 illustrates a third surgical tool
28	according to the invention; and
29	
30	Figure 13 illustrates a fourth surgical tool
31	according to the invention.
32	

31

1 Referring to Figures 1 and 2, a hernia, vaginal prolapse or such like occurs when a fascial wall 1 2 3 ruptures, forming a defect 2, i.e. a weakening or, 4 in this case, parting of the fascial wall 1. An 5 organ 3, contained by the fascial wall 1 is then 6 able to protrude through the defect 2. 7 protrusion is illustrated in Figure 2 and occurs particularly when pressure within the cavity defined 8 9 by the fascial wall 1 is raised. For example, in the case of an inguinal hernia, when a patient 10 11 coughs, intra-abdominal pressure is raised and the 12 intestines may be pushed through the defect 2 in the 13 abdominal wall. 14 15 Whilst the organ 3 that may protrude through the 16 defect 2 is usually still contained by some other membrane 4, the hernia, prolapse or such like is 17 18 inevitably painful and liable to infection or other 19 complications. An effective and desirable treatment 20 is therefore to close the defect 2 and contain the organ 3 in its normal position. 21 22 23 Referring to Figure 3, hernias, vaginal prolapse and such like are conventionally repaired by providing 24 25 sutures 5 across the defect 2 to join the tissues of 26 the fascial wall 1. In addition, it may be firstly 27 necessary to plicate (i.e. fold or reduce) the 28 membrane 4 as this may have stretched due to 29 distention of the organ 3. Plication of the 30 membrane 4 corrects the stretching and helps to 31 relieve pressure on the area of the defect 2 during 32 healing as the membrane 4 can act to contain the

organ 3 to some extent. Plication is generally

2

WO 02/078568

4 Referring to Figure 4, it is also a known method of

achieved by applying sutures 6 to the membrane 4.

32

PCT/GB02/01234

5 treating hernias to provide, additionally or

6 alternatively to sutures, a mesh 7 across the defect

7 4. This allows for the defect 2 to be repaired

8 without the parted tissues of the fascial wall 1

9 necessarily being brought together and for the

10 defect to heal without the fascial wall 1 being

11 pinched or tensioned to correct the defect 2.

12

13 Figure 5 schematically illustrates (a sagittal view

of) the female human vaginal area. The vagina 8 is

15 illustrated with its anterior portion (front) at the

top of the diagram and the posterior portion (rear)

17 at the bottom of the diagram. The opening of the

18 urethra, or urethral meatus, 9 is at the forward or

19 anterior end of the vagina 8. The central portion

of the vagina 8 forms the vaginal cavity which

21 terminates at the cervix 10. Spaced from the

rearward or posterior end of the vagina 8 is the

23 anus 11. Four areas A to D of the vaginal wall 12

are outlined in figure 5. These areas A to D are

25 those areas of the vaginal wall 12 in which vaginal

26 prolapse often occurs.

27

28 Referring to figure 6, which is a cross sectional

view along the line A-A in figure 5, it can be more

30 clearly seen that the wall 12 of the vagina 8 is

31 bounded by the bladder 13 and urethra 14, the uterus

32 15, the small bowel 16 and rectum 17. The small

33

1 bowel 16 and rectum 17 are separated by the "Pouch 2 of Douglas" PoD. 3 Area A is the lower one third of the anterior 4 vaginal wall 12 (i.e. the one third nearest the 5 entrance to the vaginal cavity) adjacent the bladder 6 13 and urethra 14. Prolapse in this area is 7 referred to as anterior or, more specifically, 8 9 urethracoele prolapse. Area B is the upper two 10 thirds of the anterior vaginal wall 12. Prolapse in 11 this area is referred to as anterior or, more 12 specifically; cystocoele prolapse. The central area of the vaginal wall 12 in which the cervix 10 is 13 located is adjacent the uterus 15 and prolapse in 14 this area is referred to as central, uterine or 15 16 vault prolapse. Area C is the upper one third of the posterior vaginal wall 12. This area of the 17 18 vaginal wall 12 is adjacent the small bowel 16 and prolapse in this area is referred to as posterior or 19 entreocoele prolapse. Finally, area D is the lower . 20 two thirds of the posterior vaginal wall and is 21 22 adjacent the rectum 17. Prolapse in this area is generally referred to as posterior or rectocoele 23 24 prolapse. 25 Conventionally, any of the above types of hernia 26 27 have been treated by providing sutures in the area of the prolapse. For example, the extent of the 28 29 defect causing the prolapse is first identified by the surgeon. Lateral sutures, i.e. sutures from one 30 side to the other of the vaginal wall 12 as seen in 31 figure 5 or right to left rather than anterior to 32

posterior, are provided across the area of the 1 2 This joins the parted tissues of the vaginal wall and repairs the defect. The organ 3 protruding through the vaginal wall is therefore 4 contained. Disadvantages of this technique include 5 anatomical distortion of the vagina due to 6 tensioning of the wall by the sutures to repair the 7 defect. 8 9 A surgical implant for use in the repair of vaginal 10 prolapse in accordance with an embodiment of the 11 present invention comprises a mesh 20. The mesh is 12 comprised of strands 22. The strands being less 13 14 than 600 µm and approximately 150 to 600 µm in 15 The strands are arranged such that they 16 form a regular network and are spaced apart from 17 each other such that for a diamond net a space of 18 between 2mm to 5mm exists between the points where 19 the strands of the mesh interact with each other In a hexagonal net arrangement the space is 20 21 between 2mm to 5mm between opposite diagonal points where the strands of the mesh interact (b). 22 23 24 It is preferable to space the strands as far as part as possible to allow blood to pass through the 25 implant and reduce the mass of the implant, while 26 providing the mesh with sufficient tensile strength 27 28 and elasticity to be effective. It can therefore be 29 appreciated that considerable variability in the 30 maximum spacing between the strands can be achieved depending of the material from with the strands are 31

34

35

comprised and the net pattern in which the strands 1 2 are arranged. 3 In the embodiment shown in figure 7a the strands are 4 5 arranged in a diamond net pattern 24, however any 6 pattern which provides suitable tensile strength an 7 elasticity may be used. 8 9 For example a hexagonal net pattern may be used as 10 shown in figure 7b. 11 Ideally in order to reduce the overall mass of the 12 13 implant the strands 22 should have as narrow a diameter as possible while still providing the mesh 14 15 20 with suitable tensile strength and elasticity. 16 The strands 22 of the mesh 20 are comprised of at 17 least two filaments 26 arranged to interact such 18 19 that pores 28 are formed between the filaments 26. 20 The pores 28 formed between the filaments 26 are 21 around 50 to 200 µm, such a spacing allowing 22 23 fibroblast through growth to occur. This fibroblast 24 through growth secures the implant 20 in place 25 within the body. Additionally and importantly the suitably sized pores allow the implant 20 to act as 26 27 a scaffold to encourage the lay down of new tissue. 28 The lay down of new tissue promotes the healing of 29 the hernia. 30 31 The filaments 26 may be formed from any 32 biocompatible material. In this embodiment the

36

1 filaments 26 are formed from polyester, wherein each polyester filament 26 is around 0.09 mm in diameter. 2 3 In the embodiment shown the filaments 26 of the 4 strands 24 are knitted together using warp knit to 5 reduce the possibility of fraying of the filaments 6 7 26 and strands 24. 8 9 Alternative suitable materials of which the filaments may be formed include polypropylene. 10 11 Suitable materials from which the mesh can be made: 12 provide sufficient tensile strength to support a 13 fascial wall during repair of a defect in the 14 15 fascial wall causing a hernia; are sufficiently inert to avoid foreign body reactions when retained 16 17 in the human body for long periods of time; can be easily sterilised to prevent the introduction of 18 infection when the mesh is implanted in the human 19 body; and have suitably easy handling 20 21 characteristics for placement in the desired 22 location in the body. 23 24 The fine warp knit of the filaments 26 provides a surgical implant which is flexible in handing, which 25 26 can be easily cut into different shapes and dimensions. As the strands 24 are formed using warp 27 knit the possibility of fraying of the edge of the 28 surgical implant 20 following production or cutting 29 of the surgical implant 20 is reduced. 30

Other methods of reducing fraying of the filaments 1 24, not arranged to form the strands using warp 2 knit, following cutting or production of the implant 3 are heat treatment, laser treatment or the like to 4 seal the edges of the surgical implant. 5 6 7 The mesh 20 may be supplied in any shape or size and 8 cut to the appropriate dimensions as required by the 9 surgeon. 10 It can be appreciated that cutting of the mesh will 11 produce an unfinished edge 30. Due to the sparse 12 13 nature of the strands that form the mesh and their 14 narrow diameter this unfinished edge does not suffer 15 from the same problems as edges of meshes of the 16 prior art. 17 18 In other words the edge produced is not rough and jagged such that it increases the likelihood of 19 20 extrusion of the edge of the mesh in situ or the 21 chance of infection. 22 As discussed an advantage of the mesh of the present 23 24 invention is that it allows the production of a mesh 25 suitable for use in hernia repair which allows substantially less foreign material to be left into 26 27 the body. 28 29 However, the mesh being flexible and insubstantial 30 is less suitable for allowing easy handling of the 31 mesh directly by a surgeon. Referring to figure 8a

37

PCT/GB02/01234

38

PCT/GB02/01234

and 8b the mesh described above may be treatable 1 using an absorbable coating 32. 2 3 The absorbable coating 32 comprises a layer of 4 absorbable material having a thickness greater than 5 that of the strands 22 of the mesh 20. For example, 6 7 the thickness of the layer of absorbable material 8 may be around 1 to 2 mm. The strands 22 of the mesh 9 20 may be entirely embedded in the absorbable coating 32 such that the outer surface of the mesh 10 20 is covered entirely of the absorbable coating 32. 11 12 In effect the entire surgical implant is encased in 13 14 the absorbable coating as shown in figure 8b. 15 Thus, the surgical implant has no gaps or holes on 16 its surface. This has the advantage of reducing the 17 18 likelihood of bacteria becoming lodged on the strands 22 of the mesh 20 before implantation of the 19 20 mesh 20. Furthermore, the absorbable coating 32 makes the mesh 20 more substantial and less flexible 21 such that it is more easily handled by a surgeon. 22 23 This is particularly useful when it is desired to 24 place the mesh in a desired location in a conventional, open surgical procedure. 25 26 27 In an alternative embodiment shown in figure 8a the 28 absorbable coating 32 comprises a layer of absorbable material applied to one face 34 of the 29 30 mesh 20, such that the mesh has a first face 34 on 31 which the absorbable material has been applied and a 32 second face 36 on which the absorbable material has

39

1 not been applied such that the first and second 2 faces 34 and 36 each have different characteristics. 3 4 It can also be envisaged that the surgical implant 5 is provided with improved surgical handling б qualities by a range of other methods. Such methods 7 including, the releasable attachment of the mesh 20 8 to a backing strip 40. This embodiment is shown in 9 figure 8c. 10 11 The backing strip may be formed from plastics 12 material and is adhered to the surgical implant 13 using releasable adhesive. 14 In a similar fashion to the absorbable coating the 15 backing strip 40 causes the mesh 20 to be more 16 substantial and less flexible such that it is more 17 easily handled by a surgeon. Following the suitable 18 19 placement of the mesh 20 the backing strip 40 can be 20 removed from the mesh 20, the mesh 20 being retained 21 in the body and the backing material 40 being 22 removed by the surgeon. Application of the backing strip 40 to the mesh 20 means the mesh 20 benefits 23 from reduced mass but that the mesh 20 and backing 24 25 strip 40 together give characteristics required for 26 surgical handling. 27 In a further embodiment the filaments of the mesh 28 29 may be comprised from bicomponent microfibres 50 or 30 composite polymers 60. These technologies provide 31 the implant with dual phase technology.

40

PCT/GB02/01234

As shown in figure 8d the bicomponent microfibres 50 1 comprise a core 52 (cutaway section shows core 2 region) and surface material 54. The surface 3 material 54 is designed such that it is absorbed by 4 the body in a matter of hours, while the core 5 material 52 remains in the body for a longer period б 7 to enable tissue ingrowth. 8 Suitable bicomponent microfibres 50 include a 9 polypropelene non absorable portion and a polylactic 10 11 acid absorbable portion. 12 The surface material 54 is present during the 13 surgical procedure when the mesh 20 is being 14 inserted and located in the patient, and provides 15 the mesh with characteristics desirable for surgical 16 handling. Following a period of insertion in the 17 body, typically a few hours, the surface material 54 18 is absorbed into the body leaving only the core 19 material 52 of the filaments 26 in the body. The 20 core material of the filament having reduced foreign 21 mass in comparison to meshes of the prior art or the 22 mesh 20 when it also includes the surface material 23 54. 24 25 As shown in figure 8e the mesh of the surgical 26 implant may be formed composite polymers 60. As 27 described for the bicomponent microfibres 50, 28 composite polymers 60 provide the surgical implant 29 with dual phase technology. A first face 62 of the 30~ mesh 20 thus having particular characteristics such . 31 as flexibility and elasticity, while a second face 32

41

1 64 of the mesh 20 provides the mesh 20 with characteristics which improved the surgical handling 2 of the mesh 20 such as strength and robustness. 3 The cutting of the mesh described causes an 4 5 unfinished edge of the mesh to be produced. unfinished mesh not being as likely to cause the б 7 same problems as the rough and jagged edges of the implants of the prior art, due to the fewer strands, 8 9 smaller diameter filaments and treatment of the mesh with absorbable coating which protects the tissue 10 from the mesh during the surgical procedure when 11 damage is most likely to occur. 12 13 14 Referring to 9a, a further embodiment of the mesh may comprise strands as discussed and more 15 16 specifically, perimeter strands. Typically the mesh 17 · is circular or the like in shape and thus this perimeter strand can be generally referred to as a 18 circumferential strand 70. 19 20 21 In the example shown in figure 9a one strand runs 22 around the circumference of the oval shape of the mesh 20. In another embodiment, several 23 24 circumferential strands 70 may be present, each circumferential strand 70 may extend over one side 25 of the oval mesh 20, i.e. around half the 26 circumference of the mesh. 27 28 As shown in figure 9b the circumferential strands 70 29 are arranged concentrically and each extends around 30 31 the mesh 20 at a different radial location.

42

An outer circumferential strand 70 extending around 1 the perimeter of the mesh 20, and further 2 circumferential strands 72 and 74 are arranged 3 inwardly of the outer circumferential strand forming 4 a perimeter spaced by a distance (a). The distance 5 a between adjacent circumferential members 70, 72 6 and 74, can vary and in this example is 20 mm. 7 8 9 Transverse strands 76 extend from the centre of the oval mesh 20 to points on the perimeter of the mesh 10 In this example, four transverse strands 76 are 78. 11 provided across the diameter of the mesh 20, 12 dividing the mesh 18 into eight angularly equal 13 14 portions. 15 The mesh 20 of this embodiment may be formed from 16 materials as previously described. Depending on the 17 material chosen the mesh may be woven, knitted or 18 extruded as one piece, or individual or groups of 19 strands can be extruded separately and joined to one 20 another. 21 22 Such a construction as described above provides a 23 24 mesh 20 with sufficient tensile strength to repair defects causing vaginal prolapse whilst having 25 minimal bulk. Similarly, such a construction 26 provides a suitably flexible yet resilient mesh for 27 handling using the surgical tools described below. 28 Referring to figures 9c and 9d, meshes 80, 82 of in 29 30 the shape of the outline having angled sides respectively, rather than oval, are illustrated. 31 32

43

These meshes have a similar structure to that 1 2 described with reference to figure 9a and b. However, the mesh has a perimeter member 80 having. 3 angled sides. Further it may have transverse 4 members arranged only to extend towards the 5 perimeter of the mesh, rather than all being across 6 7 the diameter of the mesh. This provides a more 8 uniform structure. More specifically, referring to 9 figure 9d the mesh has a transverse member 84 extending along its axis of symmetry, a transverse 10 member 86 bisecting the axis of symmetry, and four 11 further transverse members 88 extending from the 12 13 axis of symmetry to the perimeter of the mesh 90. 14 15 In addition to the pores provided by the combination 16 of filaments 26 which form the strands 22, pores can 17 be provided by rings of polypropylene positioned at the intersection of the circumferential and 18 19 transverse members. 20 Alternatively the pores may be formed by the spacing 21 of the transverse members, such that pores of a size 22 23 50-200µm suitable for enabling tissue ingrowth exist 24 between the transverse members. 25 26 To secure the mesh to a suitable location in the 27 body a number of methods can be used. The tackiness 28 of the absorbable coating may hold the mesh suitably until it is secured by tissue ingrowth. 29 30 Alternatively the surgical implant can have capsules 31 100 (not shown) of biocompatible glue for securing 32

3.2

1 the mesh 20 in place. In this example, six capsules . 2 100 comprising spheres having a diameter of 4 mm and 3 made from a rapidly absorbable material are provided around the perimeter of the mesh 20. On placement 4 5 in the body, the capsules 100 dissolve and release a 6 biocompatible glue contained within to secure the 7 mesh 20 in place. 8 Referring to figure 10, a tool 200 for inserting one 9 10 of the meshes described (usually without an 11 absorbable coating 32) comprises two channels 202, The channels 202, 204 are semi-circular in 12 13 cross-section and the channel 202 has a diameter slightly smaller than the diameter of channel 204. 1415. The channels are interconnected such that the channel 202 can be rotated inside the channel 204. 16 In use, the mesh 20 is rolled up and placed in the 17 18 space formed by the channels 202,204 in a first 19 position in which the open sides of the channels face one another to form a housing or tube. After 20 insertion into the desired location, channel 204 is 21 22 rotated inside the channel 202 to release the mesh 23 20. 24 25 Referring to figure 11, an alternative tool 210 for inserting one of the meshes described comprises an 26 elongate housing 212 around which the mesh is rolled 27 28 and secured. The tool 210 has means for trapping an edge of the mesh 20 to secure it on the housing of 29 30 the tool 212, such as a groove 214. In use, once the mesh 20 has been rolled around the housing of 31

the tool 210 it may be secured by a removable clip

44

PCT/GB02/01234

45

PCT/GB02/01234

1 or other such retaining means (not shown). After insertion of the tool 210 into the desired location, 2 the mesh 20 is released and the tool 210 is rotated 3 4 to unfurl the mesh 20. 5 6 Referring to figure 12, another alternative tool 220 7 for inserting one of the meshes described above in 8 the body comprises two arms 222 pivotally interconnected by a pivot 224. One end of each arm 9 226 has means for being releasably attached to the 10 mesh 20. The other end of each arm 228 is operable 11 to move the ends that may be attached to the mesh 20 12 13 toward or away from one another by rotation around the pivot 224. When the ends of the arms 226,228 to 14 which the mesh 20 can be attached are moved to a 15 position in which they are close to one another, the 16 17 tool 220 is substantially elongate. Furthermore, the mesh 20 is radially confined by the arms. Once 18 19 the mesh 20 has been inserted into position, the arms 226,228 can be manipulated to move the ends to 20 21 which the mesh 20 can be attached apart to unfurl 22 the mesh 20 in its intended position. 23 24 Referring to figure 13, another tool 230 for 25 inserting one of the meshes described above in its 26 desired location comprises an elongate housing 232 2.7 having a number of pairs of holes 234 spaced along its length (in this example three pairs) at the 28 29 distal end of the tool 230. The housing 232 is hollow and contains a number (in this case three) of 30 31 pairs of wires 236, made from polypropylene for example, which extend along the length of the 32

2 The wires 236 also protrude from the proximal end of

46

housing 232 and out through the pairs of holes 234.

PCT/GB02/01234

3 the housing such that they can be pushed and pulled

4 in and out of the housing 232. The ends of the

5 wires 236 that protrude from the holes 234 have

6 means for releasably attaching to points near the

7 perimeter of the mesh 20.

8

WO 02/078568

1

9 In use, the wires 236 are attached to the mesh 20

10 and retracted by pulling them back through the

11 housing 30 such that the mesh 20 is radially

12 confined close to the housing 232. Once the tool

13 230 has been inserted into the intended position,

the wires 236 are pushed into the housing 232 and

15 consequently out through the holes 234 to urge the

mesh 20 away from the housing 232. Thus, the mesh

17 20 can be unfurled in its desired location in the

18 body.

19

20 Referring once again to figure 5 in order to repair

21 a urethracoele prolapse i.e. a defect in the area A

of figure 5, the surgeon first locates the defect by

23 examining the patient in the conventional manner.

24 The extent of the defect can then be ascertained

and, if necessary, a suitable template used to

26 estimate the shape and dimensions of a preferred

27 surgical implant to repair the defect. A suitably

shaped surgical implant can then be selected.

29

30 The meshes described above are, in this example,

31 supplied in a single size. After examination of the

32 patient and estimation of the desired dimensions of

47

1 the preferred mesh, the surgeon cuts the mesh to the 2 preferred size. 3 Where the mesh comprises a circumferential member 7.0 4 the cut made in the mesh is through the transverse 5 members 76 just outward of the circumferential 6 7 member 70 corresponding most closely with the preferred size of mesh. Thus, regardless of the 8 · 9 size to which the mesh is to be cut, a circumferential member 70 defines the perimeter of 10 11 the mesh, and the perimeter of the mesh is 12 substantially smooth. This desirably reduces the 13 likelihood of infection or edge erosion once the 14 mesh is inserted in the body. 15 16 The surgeon then attaches the mesh to or inserts the 17 mesh with one of the insertion tools described 18 herein. For example, the mesh is rolled up and placed within the insertion tool 200 illustrated in 19 20 figure 10, wrapped around the insertion tool 210 illustrated in figure 11, attached to the ends of 21 the arms 222 of the insertion tool 220 illustrated 22 23 in figure 12 or attached to the ends of the wires 24 236 of the insertion tool 230 illustrated in figure 25 13. 26 27 An incision 9 is then made in the vaginal wall 12 at 28 the forward most portion of the vaginal wall 12 29 adjacent the opening of the vaginal cavity. A 30 cutting implement (not illustrated), such as 31 scissors or a specialised cutting tool, is/are then 32 inserted through the incision 9 into the area A,

X-

WO 02/078568

32

48

PCT/GB02/01234

i.e. the lower portion of the anterior vaginal wall 1 2 12. Using the cutting implement, a cut is made in the area A parallel with the surface of the vaginal 3 wall 12. In other words, a space is opened up in 4 5 the vaginal wall 12 over the area of the defect in 6 the vaginal wall 12. The cutting implement is then 7 withdrawn and the mesh 20 is inserted in the space 8 defined by the cut. 9 10 Where the insertion tool 200 illustrated in figure 11 10 is used, the tool 200 is inserted into the area A and the channel 202 rotated to a position within the 12 channel 204 to release the mesh 20. The insertion 13 tool 200 can then be retracted and the mesh unfurls 14 due to its inherent resilience or flat memory. 15 16 Should it be required to help the mesh 20 to unfurl, 17 or slightly re-position the mesh 20 defect 2, an 18 elongate tool (not shown) may be inserted through 19 the incision 9 or needles may be introduced directly 20 through the vaginal wall 12 to manipulate the mesh 21 This procedure can be viewed laproscopically through the incision 9 if desired. 22 23 Where the insertion tool 210 illustrated in figure 24 11 is used, it is desirable for the insertion tool 25 26 210 to be inserted to one side of the space defined by the cut. The mesh 20 is then released and a 27 needle inserted through the vaginal wall to hold the 28 29 released edge of the mesh 20 in position. The tool 30 210 is then rolled across the space defined by the cut in an arc having a centre of rotation around the 31

incision 9. Thus, the mesh 20 is unfurled, but no

49

PCT/GB02/01234

1 significant movement is required around the incision 2 9. 3 4 Where the insertion tool 220 illustrated in figure 5 12 is used, the insertion tool 220 is simply 6 inserted through the incision 9 and opened to expand 7 the mesh 20 into its desired location. The mesh 20 is released from the insertion tool 220 which can 8 9 then be closed and withdrawn through the incision 9. 10 11 Finally, where the insertion tool 250 illustrated in 12 Figure 13 is used, the mesh 20 is retracted by 13 withdrawing the wires 236 through their holes 234 14 and the mesh is inserted through the incision 9. 15 Once the insertion tool 230 has been inserted into its desired location, the wires 236 are urged 16 forward and out through the holes 234 to expand the 17 18 mesh in its intended position. The wires 236 can then be released from the mesh 20, withdrawn into 19 the housing 232 and the tool 230 withdrawn through 20 21 the incision 9. 22 23 Once the mesh 20 is in place, the incision may be 24 closed. 25 However, it can be desirable to secure the 20 in 26 27 place, rather than rely on the mesh 20 remaining in 28 its desired location of its own accord. In one 29 example, sutures are therefore be placed either 30 laproscopically through the incision 9 or directly through the vaginal wall 12 to hold the mesh 20 in 31 32 place. In another example, glue capsules provided

50

on the mesh 20 dissolve to secure the mesh 20 to the 1 2 tissue surrounding the space defined by the cut, or such capsules may be punctured by needles inserted 3 directly through the vaginal wall 12. 4 5 6 The surgical implant described herein is 7 advantageous over the meshes of the prior art in 8 several ways. 9 10 In particular the mesh of the present invention 11 includes smoother edges, the polyester material of the present invention being softer than 12 13 polypropylene. Further, the filaments of the present invention are narrower in diameter enabling 14 15 them to be more pliable than the strands of the meshes of the prior art. This causes the edge or 16 17 edges of the mesh of the present invention to have fewer jagged edges and thus be smoother that the 18 19 edges of meshes or the prior art. 20 In addition encasement of the mesh in an absorbable 21 22 coating further protects the tissue both during placement and for a period of time after placement 23 24 of the surgical implant. 25 Dual Phase Technology TM such as encasement in an 26 27 absorbable coating or as otherwise discussed herein 28 provides the implant with good handling 29 characteristics, further it enables the implant to 30 be more easily cut. As described above an 31 absorbable coating may protect the tissues around where the implant is to be located both during 32

PCT/GB02/01234

51

1 placement and for a period of time following 2 placement of the implant in the tissue. 3 Dual Phase Technology may also provide the implant 4 5 with memory. This memory may allow the implant to be more easily placed flat on the tissue. 6 7 the dual phase technology such as an absorbable 8 coating may provide the implant with mild adhesive 9 properties or tackiness which would aid both the locating and securing of the implant in the tissue. 10 11 12 The surgical implant described herein thus allows 13 tension free repair of hernias, particular vaginal prolopse, with minimum pain. This allows the 14 15 procedure to be performed under local anaesthetic in 16 an out patient or office setting. 17 Whilst the above embodiments of the invention have 18 been described with reference to vaginal prolapse, 19 20 the mesh and surgical tools may equally be used to repair any bodily hernia. Furthermore, whilst the 21 22 above procedure has been described in relation to a 23 urethrocoele prolapse, prolapse in other parts of the vaginal wall 12 can be treated through incisions 24 elsewhere in the vaginal wall, or other bodily 25 hernias through suitable incisions in the 26 27 appropriate tissue.

52

1	Cla	aims

2

- 3 1. A surgial implant suitable for treatment of
- 4 hernias, the implant comprising a mesh comprising
- 5 strands having a maximum residual mass density of
- $6 50 {g/m}^2$.

7

- 8 2. An implant as claimed in claim 1 wherein the
- 9 mesh has a maximum residual mass density of less
- 10 than $30g/m^2$.

11

- 12 3. A surgical implant as claimed in claims 1 or 2
- wherein the mesh comprises strands and includes
- 14 major spaces and pores, the spaces existing between
- the strands and pores formed within the strands.

16

- 17 4. An implant as claimed in any preceding claim
- wherein strands are formed from at least two
- 19 filaments.

20

- 21 5. A surgical implant as claimed in any preceding
- 22 claim wherein the strands are spaced apart to form
- 23 major spaces of 1 to 10 mm.

24

- 25 6. A surgical implant as claimed in any preceding
- 26 claim wherein the strands have a diameter of less
- 27 than 600um.

28

- 29 7. A surgical implant as claimed in any preceding
- 30 claim wherein the strands are arranged to form a
- 31 warp knit diamond or hexagonal net mesh.

53

1 8. A surgical implant as claimed in any preceding

- 2 claim wherein the strands are arranged to form a net
- 3 mesh which has isotropic or near isotropic tensile
- 4 strength and elasticity.

5

- 6 9. A surgical implant as claimed in any preceding
- 7 claim wherein the filaments have a diameter of
- 8 between 0.02 to 0.15 mm.

9.

- 10 10. A surgical implant as claimed in any preceding
- 11 claim wherein the filament of the mesh is of a
- 12 diameter 0.05 to 0.1 mm.

13

- 14 11 A surgical implant as claimed in any preceding
- 15 claim wherein a monofilament or at least two
- filaments are interwoven/knitted such that the
- 17 strands of the mesh comprise pores.

18

- 19 12. A surgical implant as claimed in any preceding
- 20 claim wherein the pores in the strands are of
- 21 between 50 to 200µm in diameter.

22

- 23 13. A surgical implant as claimed in any preceding
- 24 claim further comprising rings of material
- 25 comprising pores of between 50 to 200 µm adhered to
- on the strands of the mesh to provide pores.

27

- 28 14. A surgical implant as claimed in any preceding
- 29 claim wherein the pores in the strands are of
- 30 between 50 to $75\mu m$ in diameter.

54

1 15. A surgical implant as claimed in any preceding

- 2 claim wherein the filaments of the mesh comprise a
- 3 plastics material.

4

- 5 16. A surgical implant as claimed in any preceding
- 6 claim wherein the filaments of the mesh comprise a
- 7 synthetic material.

8

- 9 17. A surgical implant as claimed in any preceding
- 10 claim wherein the filaments of the mesh comprise an
- 11 absorbable material.

12

- 13 18. A surgical implant as claimed in any of claims
- 14 1 to 16 wherein the filaments of the mesh comprise.
- 15 polypropylene.

16

- 17 19. A surgical implant as claimed in any of claims
- 18 1 to 16 wherein the filaments of the mesh comprise
- 19 polyester.

20

- 21 20. A surgical implant as claimed in any preceding
- 22 claim wherein the implant has an absorbable coating
- which degrades within 48 hours.

24

- 25 21. A surgical implant as claimed in claim 20
- 26 wherein the absorbable coating encapsulates the mesh
- of the surgical implant.

28

- 29 22. A surgical implant as claimed in claim 20
- 30 wherein the absorbable coating is applied to at
- 31 least one face of the mesh.

55

1 23. A surgical implant as claimed in claims 20 to

- 2 22 wherein the absorbable coating comprises any
- 3 suitable soluble and biocompatible material.

4

- 5 24. A surgical implant as claimed in claims 20 to
- 6 23 wherein the absorbable coating is a soluble
- 7 hydrogel such as gelatin.

8

- 9 25. A surgical implant as claimed in claims 20 to
- 10 23 wherein the absorbable coating is a starch or
- 11 cellulose based gel.

12

- 13 26. A surgical implant as claimed in claims 20 to
- 14 23 wherein the absorbable coating is an alginate.

15

- 16 27. A surgical implant as claimed in claims 20 to
- 26 wherein the coating is of a thickness greater
- 18 than that of the mesh.

19

- 20 28. A surgical implant as claimed in any preceding
- 21 claim comprising a backing strip wherein the backing
- 22 strip is releasably attachable to the mesh.

23

- 24 29. A surgical implant as claimed in claim 28
- 25 wherein the backing strip is formed from plastics.

26

- 27 30. A surgical implant as claimed in claims 28 or
- 28 29 wherein the surgical implant is releasably
- 29 attachable to the backing strip by adhesive.

56

1 31. A surgical implant as claimed in any preceding

2 claim wherein the strands of the mesh are comprised

3 of bicomponent microfibres.

4

5 32. A surgical implant as claimed in claim 31

6 wherein the bicomponent microfibres comprise a core

7 and surface material.

8

9 33. A surgical implant as claimed in claim 32

10 wherein the surface material is capable of being

absorbed by the body in a period of less than 48

12 hours.

13

14 34. A surgical implant as claimed in claims 32 or

15 33 wherein the core material is capable of remaining

in the body for a period of time sufficient to

17 enable tissue ingrowth.

18

19 35. A surgical implant as claimed in claim 32

20 wherein the surface material is polylactic acid and

21 the core material is polypropylene.

22

23 36. A surgical implant as claimed in any preceding

24 claim wherein the surgical implant comprises

25 material that has memory.

26

27 37. A surgical implant as claimed in claim 36

wherein the surgical implant has memory which urges

29 the surgical implant to adopt a flat conformation.

57

1 38. A surgical implant as claimed in any preceding

2 claim wherein the implant has a generally curved

3 perimeter.

4

5 39. A surgical implant as claimed in any preceding

6 claim wherein the surgical implant is of width

7 between 1 cm to 10 cm and of length between 1 cm to

8 10 cm.

9

10 40. A surgical implant as claimed in any preceding

11 claim wherein the implant is any one of round,

12 circular, oval, ovoid eliptical or truncated

13 eliptical or some similar shape.

14

15 41. A surgical implant as claimed in any preceding

16 claim wherein the mesh can be cut to any desired

17 shape.

18.

19 42. A surgical implant as claimed in any preceding

20 claim wherein the mesh has at least one

21 circumferential member which extends, in use, along

22 at least part of the perimeter of the implant to

23 provide a substantially smooth edge.

24

25 43. A surgical implant as claimed in claim 42

26 wherein at least part of the perimeter of the

27 implant is defined by the circumferential member.

28

29 44. A surgical implant as claimed in claims 42 or

30 43 wherein at least 50% of the perimeter of the

implant is defined by the circumferential member(s).

58

1 45. A surgical implant as claimed in claims 42 to

2 44 wherein at least 80% of the perimeter of the

3 implant is defined by the circumferential member(s).

4

5 46. A surgical implant as claimed in claims 42 to

6 45 wherein 100% of the perimeter of the implant is

7 defined by the circumferential member(s).

8

9 47. A surgical implant as claimed in claims 42 to

10 46 wherein the perimeter of the mesh is defined, in

11 use, by one circumferential member.

12

13 48. A surgical implant as claimed in claims 42 to

14 47 wherein the mesh has a plurality of

15 circumferential members arranged at different radial

16 locations.

17

18 49. A surgical implant as claimed in claim 48

19 wherein the circumferential members are arranged to

join with one another in order to form an integral

21 mesh.

22

23 50. A surgical implant as claimed in claim 42 to 49

24 wherein the mesh comprises transverse members which

25 extend across the circumferential members joining

26 the circumferential members.

27

28 51. A surgical implant as claimed in claim 50

29 wherein the transverse members extend radially from

30 a central point to the perimeter of the implant.

59

A surgical implant as claimed in claim 50 or 51 1 2 wherein the transverse members extend toward the 3 perimeter of the implant. 4 5 A surgical implant as claimed in any preceding 6 claim wherein the mesh can be glued in place using a biocompatible glue. 7 8 A surgical implant as claimed in any preceding 9 claim comprising at least one capsule containing 10 11 biocompatable glue for securing the implant in 12 place. 13 14 55. A surgical implant as claimed in claim 54 comprising four capsules containing glue provided 15 16 around the perimeter of the surgical implant. 17 56. A surgical implant as claimed in claims 54 or 18 19 55 wherein the capsules comprise hollow thin walled 20 spheres of around 3 to 5 mm diameter including gelatin. 21 22 23 A surgical implant as claimed in claims 54 to 24 56 wherein the glue is a cyanoacrylate glue. 25 26 A minimally invasive method of treating 27 uterovaginal prolapse, the method comprising the 28 steps; 29 making a 1-2cm length incision in the vaginal 30 31 wall close to the opening of the vaginal cavity

32

and,

60

PCT/GB02/01234

1 making a subcutaneous cut, through the incision, over and surrounding the area of the 2 prolapse, which cut is substantially parallel 3 to the vaginal wall; and 4 5 6 inserting a mesh according to the present 7 invention, through the incision, into the space 8 defined by the cut. 9 A method of treating uterovaginal prolapse as 10 claimed in claim 58 wherein the incision is at the 11 posterior extremity of the prolapse sac of the 12 vaginal cavity. 13 14 A method of treating uterovaginal prolapse as 15 claimed in claim 58 wherein the incision is at the 16 anterior extremity of the prolapse sac of the 17 18 vaginal cavity. 19 A surgical tool for delivering a surgical 20 61. 21 implant as described in claims 1 to 57 22 subcutaneously through an incision, the tool being adapted to radially confine the surgical implant 23 during delivery and being operable to release the 24 mesh in its intended position. 25 26 62. A surgical tool as claimed in claim 61 27 comprising a housing and unfurling means the housing 28 and unfurling means insertable through an incision 29 in the patient, the housing and unfurling means 30 31 adapted to accommodate a rolled up mesh and separable to release the mesh, the unfurling means 32

1	capable of unfurling the rolled up mesh without any
2	significant movement around the area of the incision
3	
4	63. A surgical tool as claimed in claim 61 or 62
5	comprising two or more parts, the parts movable such
.6	that in a first position they house the mesh or
7	surgical implant and, in a second position the mesh
8	or surgical implant is released. More preferably
9	the tool comprises two semi-circular channels, an
10	inner channel having an external diameter suitable
11	for fitting inside an outer channel.
12	
13	64. Use of an implant as claimed in any of claims 1
14	to 57 in the treatment of inguinal hernia,
15	incisional hernia or uterovaginal prolapse.

1/10




Fig. 1




Fig. 2

2/10




Fig. 3





Fig. 4

3/10



SECTION A-A

Fig. 5

4/10




Fig. 6




Fig. 7b




Fig. 8c




Fig. 8d

7/10




Fig. 9a




Fig. 9b

8/10




Fig. 9c




Fig. 9d




Fig. 10




Fig. 11




Fig. 12

10/10




Fig. 13

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 02/01234

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61F2/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	FR 2 732 582 A (SGRO JEAN CLAUDE) 11 October 1996 (1996-10-11)	1,3-8, 16-19, 22,23,64
Υ	abstract	15, 20-24, 36, 38-45, 47-53, 57,61-63
	page 4, line 1 -page 5, line 32; table	
Υ	WO 00 07520 A (PELISSIER EDOUARD) 17 February 2000 (2000-02-17)	15, 38-45, 47-52
Α	page 8, line 31 -page 9, line 2; figures -/	3,7,16

Y Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the International search report
28 May 2002	05/06/2002
Name and malling address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswljk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Wolf, C

International Application No PCT/GB 02/01234

C (Continue	MAN) DOCUMENTS CONSIDEDED TO BE DELEVANT	
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	WO 99 16381 A (SCIMED LIFE SYSTEMS INC)	20-24
Α	8 April 1999 (1999-04-08) page 7, line 3 -page 10, line 6	15,16, 22,23,64
Υ	EP 0 719 527 A (SGRO JEAN CLAUDE)	21,22
Α	3 July 1996 (1996-07-03) column 4, line 20 - line 27	19,20,64
А	US 4 646 731 A (BROWER ARTHUR B) 3 March 1987 (1987-03-03) column 2, line 28 - line 49; figures	28-30
Y	FR 2 712 177 A (SGRO JEAN CLAUDE) 19 May 1995 (1995-05-19)	36
A	page 1, line 1 -page 2, line 17; figure	1,3-5,7, 8,15-19, 64
Y	WO 98 57590 A (SCIMED LIFE SYSTEMS INC) 23 December 1998 (1998-12-23) page 12, line 7 - line 29	53,57
Y	EP 0 706 778 A (ETHICON INC) 17 April 1996 (1996-04-17) the whole document	61-63
А	WO 96 03091 A (NOTARAS MITCHELL JAMES) 8 February 1996 (1996-02-08)	1,3,5-7, 9,16,18, 19
	page 3, line 27 -page 5, line 16; figure 1	
A	FR 2 735 015 A (MICROVAL) 13 December 1996 (1996–12–13) page 5, line 3 – line 26	36,64
A	EP 0 009 072 A (SIGRI ELEKTROGRAPHIT GMBH) 2 April 1980 (1980-04-02)	3,5-7, 38,40, 42-47
	page 3, line 13 - line 17; figure	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 02/01234

					1 <u>-</u>	,	
	itent document in search report		Publication date		Patent family member(s)		Publication date
FR	2732582	Α	11-10-1996	FR DE ES IT	2732582 19613317 1033775 MI960253	A1 U1	11-10-1996 10-10-1996 16-10-1996 03-10-1997
WO	0007520	Α	17-02-2000	WO AU EP	0007520 8986298 1100401	Α	17-02-2000 28-02-2000 23-05-2001
WO	9916381	A	08-04-1999	AU AU CA EP JP WO US	733858 9512598 2304296 1018980 2001517534 9916381 6197036	A A1 A1 T A1	31-05-2001 23-04-1999 08-04-1999 19-07-2000 09-10-2001 08-04-1999 06-03-2001
EP	0719527	A	03-07-1996	FR AT DE DE EP ES US	2728776 204723 69522425 69522425 0719527 2163485 5697978	T D1 T2 A1 T3	05-07-1996 15-09-2001 04-10-2001 23-05-2002 03-07-1996 01-02-2002 16-12-1997
US	4646731	Α	03-03-1987	NONE			
FR	2712177	Α	19-05-1995	FR	2712177	A1	19-05-1995
WO	9857590	Α	23-12-1998	US WO	6213126 9857590		10-04-2001 23-12-1998
EP	0706778	A	17-04-1996	AU BR CA CN EP JP ZA	3315495 9504376 2160293 1129547 0706778 8206119 9508631	A A1 A A1 A	26-04-1996 02-09-1997 14-04-1996 28-08-1996 17-04-1996 13-08-1996 14-04-1997
WO	9603091	Α	08-02-1996	AU WO	3119495 9603091		22-02-1996 08-02-1996
FR	2735015	A	13-12-1996	FR WO	2735015 9641588		13-12-1996 27-12-1996
EP	0009072	Α	02-04-1980	DE EP	2836944 0009072		13-03-1980 02-04-1980